Pazopanib in metastatic soft tissue sarcoma (STS): Results of a multi-institutional observational study.

Bilici, AhmetKoca, SinanKaraagac, MustafaEraslan, EmrahOcak, BirolAydin, Sabin GoktasGoksu, Sema SezginPaydas, SemraDerin, SumeyyeErgun, YakupYekegunduz, EmreErol, CihanOzyukseler, Deniz TatarogluDemiray, Atike GokcenKaraca, MustafaGuc, Zeynep GulsumMenekse, SerkanCinkir, Havva YesilGumusay, OzgeSakin, Abdullah2024-12-022024-12-022022-06-010732-183Xhttps://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.e23542https://doi.org/10.1200/JCO.2022.40.16_suppl.e23542https://hdl.handle.net/11452/48772Bu çalışma, 03-07, Haziran 2022 tarihlerinde düzenlenen Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) Kongresi‘nde bildiri olarak sunulmuştur.enOncologyPazopanib in metastatic soft tissue sarcoma (STS): Results of a multi-institutional observational study.Meeting Abstract0008636803045994016, Supplement S10.1200/JCO.2022.40.16_suppl.e23542